Open AccessResults of simulation of performance indicators for the oncological service when introducing innovative technologies for treatment of stage IV lung cancer
Author(s) -
С. А. Стерликов,
О. В. Зеленова,
С. И. Абрамов,
V. M. Danilov,
Yu. V. Mikhaylova,
N.A. Golubev
Publication year - 2020
Publication title -
tuberkulez i bolezni lëgkih/tuberkulëz i bolezni lëgkih
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.226
H-Index - 12
eISSN - 2542-1506
pISSN - 2075-1230
DOI - 10.21292/2075-1230-2020-98-4-15-23
Subject(s) - lung cancer , medicine , stage (stratigraphy) , cancer , lung , oncology , treatment of lung cancer , intensive care medicine , radiology , biology , paleontology
Malignant tumors of the trachea, bronchi, lungs represent a serious medical and social problem. Most cases of cancer of the trachea, bronchus, and lung are detected at stage IV, and therefore, to improve the survival of patients, a new treatment strategy is proposed based on modern data on mutagenesis and receptor status of tumor cells, which has a personalized approach for each specific case. To make managerial decisions about the introduction of innovative drugs, a forecast of expected results is required which should be improved indicators of the State Program On Healthcare Development. It has been found out that the transition to a new strategy for lung cancer chemotherapy will reduce mortality from malignant tumors by 1.2-0.7%, including lung cancer by 3.9%, as well as one-year case fatality by 3% for all malignant tumors, including 15% for lung cancer. At the same time, within 5 years after the introduction of the new strategy for lung cancer treatment, the indicator reflecting the proportion of patients with malignant tumors registered for 5 years or more is expected to decrease, which is related to specific parameters of the calculation method. The authors state that they have no conflict of interests.